+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The case for mumps vaccine



The case for mumps vaccine



New England Journal of Medicine 277(7): 376




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 044570476

Download citation: RISBibTeXText

PMID: 4378281


Related references

Clinical and serological studies of live attenuated mumps virus vaccine--inoculation of mumps vaccine singly and in combination with measles vaccine. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 45(2): 54-66, 1971

Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Clinical and Vaccine Immunology 15(9): 1425-1428, 2008

Evaluation of live attenuated S79 mumps vaccine effectiveness in mumps outbreaks: a matched case-control study. Chinese Medical Journal 122(3): 307-310, 2009

Epidemiological studies in groups of persons immunized with mumps vaccine. II. Use of the vaccine in communities after outbreak of mumps. Studii Si Cercetari de Inframicrobiologie 20(2): 91-98, 1969

The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology 31(5): 978-982, 2002

Studies on live mumps virus vaccine. V. Development of a new mumps vaccine "AM 9" by plaque cloning. Biken Journal 16(4): 161-166, 1973

Evaluation of a new mumps vaccine. Mumps virus vaccine, live, attenuated (Mumpsvax). JAMA 209(13): 2042-2042, 1969

Vaccine-induced antibodies by commercial test kits, the case of the Rubini mumps and the Edmonston-Zagreb measles vaccine strains. Vaccine 19(4-5): 396-398, 2001

Vaccine-induced antibodies assessed by commercial test kits, the case of the Rubini mumps and the Edmonston-Zagreb measles vaccine strains. Vaccine 19(4-5): 396-398, 15 October, 2000

Immunogenicity and safety of measles-mumps-rubella-varicella MMRV vaccine followed by one dose of varicella vaccine in children aged 15 monthsa“2 years or 2a“6 years primed with measles-mumps-rubella MMR vaccine. 2009

Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine 27(3): 446-453, 2008

Clinical analysis of measles mumps and rubella vaccine meningitis comparative study of mumps mumps meningitis and mmr meningitis. Jikeikai Medical Journal 38(4): 361-368, 1991

Live anti-mumps vaccine. II. Epidemiological effectiveness of the immunization of children with a single intradermal injection of live anti-mumps vaccine. Acta Virologica 2(3): 145-151, 1958

Evaluation of mumps vaccine given after exposure to mumps, with special reference to the exposed adult. Pediatrics 37(2): 304-315, 1966

Prevention of mumps in preschool institutions using a live mumps vaccine made from strain L-3. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1988(4): 39-42, 1988